Investigation of the bioequivalence of two lansoprazole formulations in healthy Chinese volunteers after a single oral administration

References

• Alai M, Lin WJ. 2015. Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations. Int J Nanomedicine. 10:4029–4041.
   PubMed Web of Science ®Google Scholar
• Barrett JS, Batra V, Chow A, Cook J, Gould AL, Heller AH, et al. 2000. PhRMA perspective on population and individual bioequivalence. J Clin Pharmacol. 40:561–570.
   PubMed Web of Science ®Google Scholar
• Davit B, Braddy AC, Conner DP, Yu LX. 2013. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 15:974–990.
   PubMed Web of Science ®Google Scholar
• Dugger HA, Carlson JD, Henderson W, Erdmann GR, Alam SM, Dham R, et al. 2001. Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers. Eur J Pharm Biopharm. 51:153–157.
   PubMed Web of Science ®Google Scholar
• Frazzoni M, De Micheli E, Grisendi A, Savarino V. 2002. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. Aliment Pharmacol Ther. 16:35–39.
   PubMed Web of Science ®Google Scholar
• Gremse DA. 2001. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert Opin Pharmacother. 2:1663–1670.
   PubMedGoogle Scholar
• Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population, 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf.
   Google Scholar
• ICH. 1996. ICH harmonization tripartite guideline. Guidelines for good clinical practice. International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human uses, Geneva, Switzerland.
   Google Scholar
• Inatomi N, Nitta K, Sakurai Y. 2008. Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg). Nihon Yakurigaku Zasshi. 131:149–156.
   PubMedGoogle Scholar
• Miner P, Jr, Katz PO, Chen Y, Sostek M. 2003. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 98:2616–2620.
   PubMed Web of Science ®Google Scholar
• Oliveira CH, Barrientos-Astigarraga RE, Abib E, Mendes GD, da Silva DR, de Nucci G. 2003. Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 783:453–459.
   PubMed Web of Science ®Google Scholar
• Rediguieri CF, Cristofoletti R, Soares KC, Tavares-Neto J. 2014. Similarities and differences of international guidelines for bioequivalence: an update of the Brazilian requirements. AAPS J. 16:350–351.
   PubMed Web of Science ®Google Scholar
• Schulz HU, Steinijans VW. 1992. Striving for standards in bioequivalence assessment: a review. Int J Clin Pharmacol Ther Toxicol. 30:S1–S6.
   PubMed Web of Science ®Google Scholar
• Uno T, Yasui-Furukori N, Takahata T, Suqawara K, Tateishi T. 2005. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci. 816:309–314.
   PubMed Web of Science ®Google Scholar
• USP DI, 18th Edition, Lansoprazole, Vol. 1, United states Pharmacopoeial Convention Inc., Rockville, MD, 1998, pp. 1795–1797.
   Google Scholar
• Welage LS, Berardi RR. 2000. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc. 40:52–62.
   Google Scholar
• World Medical Association. 2008. “Declaration of Helsinki” as Amended by the 59th World Medical Assembly. Seoul, South Korea: World Medical Association Inc.
   Google Scholar
• Wu GL, Zhou HL, Shentu JZ, He QJ, Yang B. 2008. Determination of lansoprazole in human plasma by rapid resolution liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. J Pharm Biomed Anal. 48:1485–1489.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Ye Y, Liang D, Guo C, Li L. 2015. Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H. pylori-associated duodenal ulcer. Int J Physiol Pathophysiol Pharmacol. 7:158–164.
   PubMedGoogle Scholar
• Zhang D, Zhang Y, Liu M, Wang X, Yang M, Han J, et al. 2013. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 38:209–215.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Wei SJ, Yang XY, Zhang WP, Wang XY, Dang HW. 2014. Effects of genetic polymorphisms of CYP2C19*2/*3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects. Int J Clin Pharmacol Ther. 52:850–855.
   PubMed Web of Science ®Google Scholar